Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Conor D TweedAngela M CrookEvans I AmukoyeRodney DawsonAndreas H DiaconMadeline HanekomTimothy D McHughCarl M MendelSarah K MeredithMichael E MurphySaraswathi E MurthyAndrew J NunnPatrick P J PhillipsKasha P SinghMelvin SpigelmanGenevieve H WillsStephen H GillespiePublished in: BMC infectious diseases (2018)
Most AEs considered related to standard therapy occurred in the intensive phase of treatment with female patients and HIV-positive patients demonstrating a significantly higher risk of AEs during treatment. Almost a tenth of standard therapy patients had a significant side effect, whereas both experimental arms recorded a lower incidence of toxicity. That patients with one or more AE are more likely to fail treatment suggests that treatment outcomes could be improved by identifying such patients through targeted monitoring.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- hiv positive
- prognostic factors
- stem cells
- emergency department
- oxidative stress
- mycobacterium tuberculosis
- south africa
- men who have sex with men
- patient reported outcomes
- squamous cell carcinoma
- combination therapy
- replacement therapy
- smoking cessation
- drug induced